Trial Profile
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Nov 2015
Price :
$35
*
At a glance
- Drugs Melphalan flufenamide (Primary)
- Indications Advanced breast cancer; Bladder cancer; Lymphoma; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Oncopeptides
- 13 Nov 2015 New trial record
- 10 Nov 2015 Results published in the Investigational New Drugs